Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ATRC 
AtriCure Inc (ATRC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/25/2026: ATRC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $49.38
1 Year Target Price $49.38
| 5 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.55B USD | Price to earnings Ratio - | 1Y Target Price 49.38 |
Price to earnings Ratio - | 1Y Target Price 49.38 | ||
Volume (30-day avg) 9 | Beta 1.41 | 52 Weeks Range 28.29 - 43.18 | Updated Date 02/24/2026 |
52 Weeks Range 28.29 - 43.18 | Updated Date 02/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-02-24 | When - | Estimate -0.0991 | Actual 0.06 |
Profitability
Profit Margin -2.14% | Operating Margin (TTM) 1.77% |
Management Effectiveness
Return on Assets (TTM) -0.94% | Return on Equity (TTM) -2.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1663716520 | Price to Sales(TTM) 2.9 |
Enterprise Value 1663716520 | Price to Sales(TTM) 2.9 | ||
Enterprise Value to Revenue 3.33 | Enterprise Value to EBITDA -135.97 | Shares Outstanding 49809901 | Shares Floating 48066056 |
Shares Outstanding 49809901 | Shares Floating 48066056 | ||
Percent Insiders 3.43 | Percent Institutions 100.88 |
Upturn AI SWOT
AtriCure Inc
Company Overview
History and Background
AtriCure Inc. was founded in 2000 by Dr. Brian T. Fitzgerald. The company is a pioneer in the development and commercialization of innovative medical technologies for the treatment of cardiac arrhythmias, particularly atrial fibrillation (AFib). Key milestones include the development of its proprietary ablation systems, FDA clearances for various indications, and expansion into new markets and product lines. AtriCure has evolved from a startup focused on a specific surgical approach to a comprehensive solutions provider for a wide range of cardiac ablation procedures.
Core Business Areas
- Atrial Fibrillation (AFib) Solutions: This segment focuses on providing a comprehensive portfolio of medical devices for the surgical treatment of AFib. This includes ablation systems (both open and minimally invasive), surgical meshes, and accessories designed to create durable lesions that isolate areas of the heart causing AFib. The company aims to offer a complete solution for electrophysiologists and cardiac surgeons.
- Hepatobiliary and Pancreatic (HPB) Solutions: AtriCure has expanded its offerings to include solutions for HPB surgery, primarily focusing on devices for sealing and dividing blood vessels and tissue. This segment leverages the company's expertise in energy-based surgical devices and aims to provide innovative tools for complex HPB procedures.
Leadership and Structure
AtriCure Inc. is led by a seasoned executive team. Brian T. Cook serves as the President and Chief Executive Officer. The company operates under a standard corporate structure with functional departments for research and development, manufacturing, sales and marketing, finance, and regulatory affairs. Its board of directors oversees the strategic direction of the company.
Top Products and Market Share
Key Offerings
- CoolEdgeu00ae Linear Ablator: A next-generation cryoablation system designed for precise and durable lesions in the treatment of AFib. It offers advanced control and visualization features. Competitors include Medtronic (using various ablation technologies) and Abbott (with their cardiac ablation portfolio). Precise market share data for individual products is proprietary, but AtriCure is a significant player in the surgical AFib ablation market.
- Isolatoru00ae Transseptal System: This system is used for creating transmural lesions in the left atrium during AFib surgery. It is a key component of AtriCure's surgical AFib treatment portfolio. Similar to other products, specific market share is not publicly disclosed, but it contributes to AtriCure's strong position in surgical AFib.
- HEPA-DRIVEu00ae and VASCULOSEALu00ae: These are part of AtriCure's HPB solutions, designed for vessel sealing and division in complex abdominal surgeries. They compete with various surgical stapling and sealing devices from companies like Medtronic, Johnson & Johnson (Ethicon), and B. Braun.
Market Dynamics
Industry Overview
AtriCure operates within the rapidly evolving medical device industry, specifically focusing on cardiovascular and surgical solutions. The cardiac arrhythmia treatment market is driven by an aging global population, increasing prevalence of AFib, and advancements in minimally invasive surgical techniques. The HPB surgical device market is characterized by a need for precise, efficient, and safe tools for complex procedures.
Positioning
AtriCure is positioned as a leading innovator in surgical treatments for AFib, particularly known for its comprehensive portfolio and focus on clinical outcomes. Its early mover advantage in surgical ablation has given it a strong foothold. The expansion into HPB solutions diversifies its revenue streams and leverages its core technology expertise. Competitive advantages include its patented technologies, strong surgeon relationships, and a growing clinical evidence base.
Total Addressable Market (TAM)
The total addressable market for cardiac ablation, particularly for AFib, is substantial and growing, estimated to be in the billions of dollars globally. The HPB surgical device market also represents a significant TAM. AtriCure is well-positioned to capture a growing share of the surgical AFib market and is actively expanding its presence in the HPB segment.
Upturn SWOT Analysis
Strengths
- Pioneer and market leader in surgical AFib ablation.
- Comprehensive product portfolio for AFib treatment.
- Proprietary technologies and patents.
- Strong relationships with cardiac surgeons.
- Expanding presence in the HPB market.
- Growing body of clinical evidence supporting its products.
Weaknesses
- Reliance on surgical procedures, which can be more invasive than catheter-based approaches.
- Potential for reimbursement challenges in certain markets.
- Competition from established large medical device companies.
- Long sales cycles typical for medical device adoption.
Opportunities
- Increasing global prevalence of AFib.
- Advancements in minimally invasive surgical techniques.
- Expansion into new geographic markets.
- Development of next-generation ablation technologies.
- Further penetration into the HPB surgical market.
- Potential for partnerships and collaborations.
Threats
- Intense competition from both established and emerging players.
- Shifting treatment paradigms towards catheter-based ablation.
- Regulatory hurdles and potential for product recalls.
- Economic downturns impacting healthcare spending.
- Changes in healthcare policies and reimbursement rates.
Competitors and Market Share
Key Competitors
- Medtronic plc (MDT)
- Abbott Laboratories (ABT)
- Boston Scientific Corporation (BSX)
- Johnson & Johnson (JNJ) - Ethicon
Competitive Landscape
AtriCure's advantage lies in its specialization and pioneering role in surgical AFib ablation. Competitors like Medtronic and Abbott offer broader portfolios in cardiac rhythm management and are strong in catheter-based ablation, posing a significant challenge. Johnson & Johnson and Boston Scientific also compete with various surgical and interventional devices. AtriCure's ability to offer a complete surgical solution and its strong surgeon relationships are key differentiators.
Growth Trajectory and Initiatives
Historical Growth: AtriCure has experienced consistent historical growth, primarily fueled by the increasing adoption of its surgical AFib ablation systems. The company has successfully expanded its product offerings and market reach, leading to a steady upward trend in revenue and market share within its niche.
Future Projections: Future growth projections for AtriCure are generally positive, driven by the increasing prevalence of AFib globally, the ongoing shift towards less invasive surgical techniques, and the company's expansion into new product categories like HPB solutions. Analyst estimates often predict continued double-digit revenue growth.
Recent Initiatives: Recent initiatives include the expansion of its sales force, continued investment in clinical research to further support its products, development and launch of next-generation ablation technologies, and strategic focus on growing its Hepatobiliary and Pancreatic (HPB) business segment.
Summary
AtriCure Inc. is a strong player in the growing cardiac arrhythmia market, particularly in surgical AFib treatment, with a well-established product line and a focus on innovation. Its expansion into HPB solutions offers diversification. However, it faces significant competition from larger medical device companies and the evolving landscape of ablation technologies. Continued investment in R&D and market expansion will be crucial for sustained growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- AtriCure Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Research Reports
- Financial News Outlets
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Stock market investments are subject to risk. Past performance is not indicative of future results. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AtriCure Inc
Exchange NASDAQ | Headquaters Mason, OH, United States | ||
IPO Launch date 2005-08-05 | CEO, President & Director Mr. Michael H. Carrel | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1350 | Website https://www.atricure.com |
Full time employees 1350 | Website https://www.atricure.com | ||
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.